{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T10:01:26Z","timestamp":1775728886714,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s12325-025-03483-2","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T08:14:36Z","timestamp":1770452076000},"page":"1500-1520","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Measuring What Matters to Patients with Pompe Disease: A Review of Clinical Outcome Assessments for Capturing Treatment Benefits of Innovative Novel Therapies"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2125-4734","authenticated-orcid":false,"given":"Diana","family":"Rofail","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"France","family":"Ginchereau Sowell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9739-6598","authenticated-orcid":false,"given":"Betsy","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stella","family":"Karantzoulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreja","family":"Avbersek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,7]]},"reference":[{"key":"3483_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.1221140","volume":"11","author":"R Colburn","year":"2023","unstructured":"Colburn R, Lapidus D. An analysis of Pompe newborn screening data: a new prevalence at birth, insight and discussion. Front Pediatr. 2023;11:1221140. https:\/\/doi.org\/10.3389\/fped.2023.1221140.","journal-title":"Front Pediatr"},{"issue":"11","key":"3483_CR2","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s11940-022-00736-1","volume":"24","author":"D Stevens","year":"2022","unstructured":"Stevens D, Milani-Nejad S, Mozaffar T. Pompe disease: a clinical, diagnostic, and therapeutic overview. Curr Treat Options Neurol. 2022;24(11):573\u201388. https:\/\/doi.org\/10.1007\/s11940-022-00736-1.","journal-title":"Curr Treat Options Neurol"},{"issue":"2","key":"3483_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.34763\/jmotherandchild.20202402si.2001.000002","volume":"24","author":"JE Davison","year":"2020","unstructured":"Davison JE. Advances in diagnosis and management of Pompe disease. J Mother Child. 2020;24(2):3\u20138. https:\/\/doi.org\/10.34763\/jmotherandchild.20202402si.2001.000002.","journal-title":"J Mother Child"},{"issue":"5","key":"3483_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","volume":"8","author":"PS Kishnani","year":"2006","unstructured":"Kishnani PS, Steiner RD, Bali D, et al. Pompe disease diagnosis and management guideline. Genet Med. 2006;8(5):267\u201388. https:\/\/doi.org\/10.1097\/01.gim.0000218152.87434.f3.","journal-title":"Genet Med"},{"issue":"13","key":"3483_CR5","doi-asserted-by":"publisher","first-page":"284","DOI":"10.21037\/atm.2019.07.24","volume":"7","author":"A Toscano","year":"2019","unstructured":"Toscano A, Rodolico C, Musumeci O. Multisystem late onset Pompe disease (LOPD): an update on clinical aspects. Ann Transl Med. 2019;7(13):284. https:\/\/doi.org\/10.21037\/atm.2019.07.24.","journal-title":"Ann Transl Med"},{"issue":"1","key":"3483_CR6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12883-017-0983-2","volume":"17","author":"B Schoser","year":"2017","unstructured":"Schoser B, Bilder DA, Dimmock D, Gupta D, James ES, Prasad S. The humanistic burden of Pompe disease: are there still unmet needs? A systematic review. BMC Neurol. 2017;17(1):202. https:\/\/doi.org\/10.1186\/s12883-017-0983-2.","journal-title":"BMC Neurol"},{"issue":"4","key":"3483_CR7","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s41669-019-0142-3","volume":"3","author":"B Schoser","year":"2019","unstructured":"Schoser B, Hahn A, James E, Gupta D, Gitlin M, Prasad S. A systematic review of the health economics of Pompe disease. Pharmacoecon Open. 2019;3(4):479\u201393. https:\/\/doi.org\/10.1007\/s41669-019-0142-3.","journal-title":"Pharmacoecon Open"},{"issue":"19","key":"3483_CR8","doi-asserted-by":"publisher","first-page":"e1756","DOI":"10.1212\/wnl.0000000000008441","volume":"93","author":"L Harlaar","year":"2019","unstructured":"Harlaar L, Hogrel JY, Perniconi B, et al. Large variation in effects during 10\u00a0years of enzyme therapy in adults with Pompe disease. Neurology. 2019;93(19):e1756\u201367. https:\/\/doi.org\/10.1212\/wnl.0000000000008441.","journal-title":"Neurology"},{"issue":"23","key":"3483_CR9","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1212\/wnl.0000000000004711","volume":"89","author":"E Kuperus","year":"2017","unstructured":"Kuperus E, Kruijshaar ME, Wens SCA, et al. Long-term benefit of enzyme replacement therapy in Pompe disease: a 5-year prospective study. Neurology. 2017;89(23):2365\u201373. https:\/\/doi.org\/10.1212\/wnl.0000000000004711.","journal-title":"Neurology"},{"issue":"4","key":"3483_CR10","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ymgme.2016.01.013","volume":"117","author":"KM Stepien","year":"2016","unstructured":"Stepien KM, Hendriksz CJ, Roberts M, Sharma R. Observational clinical study of 22 adult-onset Pompe disease patients undergoing enzyme replacement therapy over 5years. Mol Genet Metab. 2016;117(4):413\u20138. https:\/\/doi.org\/10.1016\/j.ymgme.2016.01.013.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"3483_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","volume":"68","author":"PS Kishnani","year":"2007","unstructured":"Kishnani PS, Corzo D, Nicolino M, et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology. 2007;68(2):99\u2013109. https:\/\/doi.org\/10.1212\/01.wnl.0000251268.41188.04.","journal-title":"Neurology"},{"issue":"Suppl 1","key":"3483_CR12","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1542\/peds.2016-0280E","volume":"140","author":"DF Kronn","year":"2017","unstructured":"Kronn DF, Day-Salvatore D, Hwu WL, et al. Management of confirmed newborn-screened patients with Pompe disease across the disease spectrum. Pediatrics. 2017;140(Suppl 1):S24\u201345. https:\/\/doi.org\/10.1542\/peds.2016-0280E.","journal-title":"Pediatrics"},{"key":"3483_CR13","unstructured":"Food and Drug Administration: FDA patient-focused drug development guidance series for enhancing the incorporation of the patient\u2019s voice in medical product development and regulatory decision making. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical. 2020. Accessed Sept 27, 2022."},{"issue":"6","key":"3483_CR14","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1017\/s0266462316000568","volume":"32","author":"PA Miller","year":"2016","unstructured":"Miller PA, Mulla SM, Adams-Webber T, Sivji Y, Guyatt GH, Johnston BC. Patient-reported outcomes in rare lysosomal storage diseases: key informant interviews and a systematic review protocol. Int J Technol Assess Health Care. 2016;32(6):393\u20139. https:\/\/doi.org\/10.1017\/s0266462316000568.","journal-title":"Int J Technol Assess Health Care"},{"key":"3483_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jclinepi.2016.06.010","volume":"79","author":"BC Johnston","year":"2016","unstructured":"Johnston BC, Miller PA, Agarwal A, et al. Limited responsiveness related to the minimal important difference of patient-reported outcomes in rare diseases. J Clin Epidemiol. 2016;79:10\u201321. https:\/\/doi.org\/10.1016\/j.jclinepi.2016.06.010.","journal-title":"J Clin Epidemiol"},{"key":"3483_CR16","unstructured":"Food and Drug Administration: Patient-focused drug development guidance public workshop: Incorporating clinical outcome assessments into endpoints for regulatory decision-making. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/public-workshop-patient-focused-drug-development-guidance-4-incorporating-clinical-outcome. 2019. Accessed June 17, 2024."},{"issue":"4","key":"3483_CR17","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s40120-025-00740-y","volume":"14","author":"D Rofail","year":"2025","unstructured":"Rofail D, Chladek M, Williams B, et al. Advancing future amyotrophic lateral sclerosis medicines by incorporating the patient voice into patient-centered holistic measurement strategies for clinical and real-world studies: results from targeted literature reviews. Neurol Ther. 2025;14(4):1311\u201343. https:\/\/doi.org\/10.1007\/s40120-025-00740-y.","journal-title":"Neurol Ther"},{"issue":"5","key":"3483_CR18","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1001\/jama.1968.03150050051011","volume":"206","author":"LS King","year":"1968","unstructured":"King LS. Signs and symptoms. JAMA. 1968;206(5):1063\u20135. https:\/\/doi.org\/10.1001\/jama.1968.03150050051011.","journal-title":"JAMA"},{"issue":"3","key":"3483_CR19","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/s1521-6942(03)00025-1","volume":"17","author":"G Stucki","year":"2003","unstructured":"Stucki G, Sigl T. Assessment of the impact of disease on the individual. Best Pract Res Clin Rheumatol. 2003;17(3):451\u201373. https:\/\/doi.org\/10.1016\/s1521-6942(03)00025-1.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"10","key":"3483_CR20","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1177\/0141076812472616","volume":"106","author":"CJ Golics","year":"2013","unstructured":"Golics CJ, Basra MK, Finlay AY, Salek S. The impact of disease on family members: a critical aspect of medical care. J R Soc Med. 2013;106(10):399\u2013407. https:\/\/doi.org\/10.1177\/0141076812472616.","journal-title":"J R Soc Med"},{"key":"3483_CR21","unstructured":"Mokkink LB, Prinsen CAC, Patrick DL, et al. COSMIN study design checklist for patient-reported outcome measurement instruments. https:\/\/www.cosmin.nl\/wp-content\/uploads\/COSMIN-study-designing-checklist_final.pdf. 2019. Accessed Nov 12, 2024."},{"key":"3483_CR22","unstructured":"Food and Drug Administration: Patient-focused drug development: Selecting, developing, or modifying fit-for-purpose clinical outcome assessments. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-incorporating-clinical-outcome-assessments-endpoints-regulatory. 2022. Accessed Dec 20, 2023."},{"issue":"1","key":"3483_CR23","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s13023-021-02067-x","volume":"16","author":"A Hamed","year":"2021","unstructured":"Hamed A, An Haack K, Gwaltney C, et al. Qualitative interviews to improve patient-reported outcome measures in late-onset Pompe disease: the patient perspective. Orphanet J Rare Dis. 2021;16(1):428. https:\/\/doi.org\/10.1186\/s13023-021-02067-x.","journal-title":"Orphanet J Rare Dis"},{"key":"3483_CR24","unstructured":"Hughes D, Bashorum L, Muri A, et al. Living with Pompe disease in the UK: Characterizing the patient journey; burden on physical and emotional quality of life; and impact of COVID-19. Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. Nashville, TN. 2022."},{"key":"3483_CR25","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13023-015-0334-6","volume":"10","author":"TA Kanters","year":"2015","unstructured":"Kanters TA, Redekop WK, Rutten-Van M\u00f6lken MP, et al. A conceptual disease model for adult Pompe disease. Orphanet J Rare Dis. 2015;10:112. https:\/\/doi.org\/10.1186\/s13023-015-0334-6.","journal-title":"Orphanet J Rare Dis"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03483-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03483-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03483-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T09:13:40Z","timestamp":1775726020000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03483-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,7]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["3483"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03483-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,7]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Diana Rofail is a full-time employee of Regeneron Pharmaceuticals, Inc., and holds stock in Regeneron Pharmaceuticals, Inc. and Roche. Nick Patel and Andreja Avbersek are full-time employees of Regeneron Pharmaceuticals, Inc., and hold stock in Regeneron Pharmaceuticals, Inc. France Ginchereau Sowell, Betsy Williams, and Stella Karantzoulis are employees of IQVIA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was non-interventional, comprising of comprehensive literature reviews using secondary data; no patients were involved in this study. Therefore, clinical research ethics committee or independent review board approval was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}